Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery

US9796977B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9796977-B2
Application numberUS-201514719513-A
CountryUS
Kind codeB2
Filing dateMay 22, 2015
Priority dateNov 5, 2010
Publication dateOct 24, 2017
Grant dateOct 24, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

First claim

Opening claim text (preview).

What is claimed is: 1. A cationic lipid of Formula A: wherein: R 1 is selected from H and (C 1 -C 6 )alkyl, wherein said alkyl is optionally substituted with one to three substituents selected from R″; n is 1 and m is 2 or 3; or m is 1 and n is 2 or 3; X is O; L 1 is C 12 -C 24 alkenyl, said alkenyl optionally substituted with one or more substituents selected from R″; and L 2 is unsubstituted C 3 -C 9 alkyl; R″ is independently selected from H and (C 1 -C 6 )alkyl; or any pharmaceutically acceptable salt or stereoisomer thereof. 2. A lipid nanoparticle comprising a cationic lipid according to claim 1 . 3. The lipid nanoparticle according to claim 2 further comprises an oligonucleotide. 4. The lipid nanoparticle according to claim 3 wherein the oligonucleotide is siRNA or miRNA. 5. The lipid nanoparticle according to claim 4 wherein the oligonucleotide is siRNA.

Assignees

Inventors

Classifications

  • Oxygen atoms · CPC title

  • Special delivery means, e.g. tissue-specific · CPC title

  • Organic compounds, e.g. fats, sugars · CPC title

  • C07D207/12Primary

    Oxygen or sulfur atoms · CPC title

  • against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9796977B2 cover?
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. …
Who is the assignee on this patent?
Sirna Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification C07D207/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).